Lyme disease
The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.
The test relies on using quantitative PCR to target genes encoded by prophages — viruses present in Lyme-causing bacteria, which can be easier to detect than the bacteria itself.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
NIH Grants HelixBind $3M for Early Detection Lyme Test
The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.